A Phase IV, Multi-center, Open-label Study to Assess Clinical Recurrence Related to Compliance With Treatment With MMX Mesalamine 2.4g/Day Given Once Daily for the Maintenance of Quiescent Ulcerative Colitis (UC).
Phase of Trial: Phase IV
Latest Information Update: 21 Oct 2011
At a glance
- Drugs Mesalazine (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms SIMPLE
- Sponsors Shire Pharmaceutical Development
- 10 Nov 2009 Actual end date (Jul 2009) and actual number of patients (290) added as reported by ClinicalTrials.gov.
- 10 Nov 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 24 Oct 2009 New trial record